Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of CN-105 peptide injection in acute supratentorial intracerebral hemorrhage
CTR20220517Phase 2Active
- Sponsor
- Kunpeng Tailing
- Start
- Aug 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of CN-105 in intracerebral hemorrhage (ICH), sponsored by Kunpeng Tailing. Started Aug 2022; status: active.
02
Drugs
CN-105
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on CTR20220517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220517.